Generic placeholder image

Current Aging Science

Author(s): Kornanong Yuenyongchaiwat* and Chareeporn Akekawatchai

DOI: 10.2174/1874609815666220513141300

DownloadDownload PDF Flyer Cite As
Systemic Inflammation in Sarcopenia Alter Functional Capacity in Thai Community-dwelling Older People: A Preliminary Observational Study

Page: [274 - 281] Pages: 8

  • * (Excluding Mailing and Handling)

Abstract

Background: Sarcopenia is linked to the loss of muscle mass in older adults, leading to impaired functional capacity and quality of life. In addition, this finding was recognized as an agerelated chronic inflammatory process. We aimed to determine the relationship between sarcopenia, functional capacity, and inflammatory biomarkers and subsequent prediction of inflammatory biomarkers in older adults.

Methods: A total of 126 women and men aged ≥ 60 years were enrolled. Participants were required to complete a handgrip dynamometer, 6-meter walk test, and bioimpedance analysis. Diagnosis was based on the definition of sarcopenia from the Asian Working Group for Sarcopenia 2019. Prior to performing a 6-minute walking test (i.e., functional capacity testing), blood samples were drawn for a C-reactive protein (CRP) test.

Results: A total of 12.70% were categorized as having sarcopenia. Significant differences in CRP and functional capacity between the sarcopenia and non-sarcopenia groups were found (p <.05). Older people with high CRP levels had significantly reduced functional capacity and slow gait speed.

Conclusions: Poor functional capacity was associated with increased CRP levels, which might be due to the development of age-related inflammation. Older patients with sarcopenia may be at higher risk for functional decline.

Keywords: Sarcopenia, inflammatory markers, functional capacity, older people, prevalence, community.

Graphical Abstract

[1]
Chang KV, Hsu TH, Wu WT, Huang KC, Hand DS. Association between sarcopenia and cognitive impairment: A systematic review and metaanalysis. J Am Med Dir Assoc 2016; 17(12): 1164.e7-64.e15.
[http://dx.doi.org/10.1016/j.jamda.2016.09.013]
[2]
Dos Santos L, Cyrino ES, Antunes M, Santos DA, Sardinha LB. Sarcopenia and physical independence in older adults: The independent and synergic role of muscle mass and muscle function. J Cachexia Sarcopenia Muscle 2017; 8(2): 245-50.
[http://dx.doi.org/10.1002/jcsm.12160] [PMID: 27897417]
[3]
Kim M, Won CW. Prevalence of sarcopenia in community-dwelling older adults using the definition of the European Working Group on Sarcopenia in Older People 2: Findings from the Korean Frailty and Aging Cohort Study. Age Ageing 2019; 48(6): 910-6.
[http://dx.doi.org/10.1093/ageing/afz091] [PMID: 31329815]
[4]
Steffl M, Bohannon RW, Sontakova L, Tufano JJ, Shiells K, Holmerova I. Relationship between sarcopenia and physical activity in older people: A systematic review and meta-analysis. Clin Interv Aging 2017; 12: 835-45.
[http://dx.doi.org/10.2147/CIA.S132940] [PMID: 28553092]
[5]
Woo J, Leung J, Morley JE. Defining sarcopenia in terms of incident adverse outcomes. J Am Med Dir Assoc 2015; 16(3): 247-52.
[http://dx.doi.org/10.1016/j.jamda.2014.11.013] [PMID: 25548028]
[6]
Yoshimura N, Muraki S, Oka H, et al. Is osteoporosis a predictor for future sarcopenia or vice versa? Four-year observations between the second and third ROAD study surveys. Osteoporos Int 2017; 28(1): 189-99.
[http://dx.doi.org/10.1007/s00198-016-3823-0] [PMID: 27885410]
[7]
Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treat-ment. J Am Med Dir Assoc 2020; 21(3): 300-307.e2.
[http://dx.doi.org/10.1016/j.jamda.2019.12.012] [PMID: 32033882]
[8]
Cruz-Jentoft AJ, Landi F, Schneider SM, et al. Prevalence of and interventions for sarcopenia in ageing adults: A systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing 2014; 43(6): 748-59.
[http://dx.doi.org/10.1093/ageing/afu115] [PMID: 25241753]
[9]
Ethgen O, Beaudart C, Buckinx F, Bruyère O, Reginster JY. The future prevalence of sarcopenia in Europe: A claim of public health ac-tion. Calcif Tissue Int 2017; 100(3): 229-34.
[http://dx.doi.org/10.1007/s00223-016-0220-9] [PMID: 28012107]
[10]
Rizzoli R, Reginster JY, Arnal JF, et al. Quality of life in sarcopenia and frailty. Calcif Tissue Int 2013; 93(2): 101-20.
[http://dx.doi.org/10.1007/s00223-013-9758-y] [PMID: 23828275]
[11]
Dalle S, Rossmeislova L, Koppo K. The role of inflammationin age-related sarcopenia. Front Physiol 2017; 12: 1045.
[http://dx.doi.org/10.3389/fphys.2017.01045]
[12]
Tuttle CSL, Thang LAN, Maier AB. Markers of inflammation and their association with muscle strength and mass: A systematic review and meta-analysis. Ageing Res Rev 2020; 64: 101185.
[http://dx.doi.org/10.1016/j.arr.2020.101185] [PMID: 32992047]
[13]
Wu X, Li X, Xu M, Zhang Z, He L, Li Y. Sarcopenia prevalence and associated factors among older Chinese population: Findings from the China Health and Retirement Longitudinal Study. PLoS One 2021; 16(3): e0247617.
[http://dx.doi.org/10.1371/journal.pone.0247617] [PMID: 33661964]
[14]
Schaap LA, Pluijm SMF, Deeg DJH, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med 2006; 119(6): 526.e9-526.e17.
[http://dx.doi.org/10.1016/j.amjmed.2005.10.049] [PMID: 16750969]
[15]
Tang Y, Fung E, Xu A, Lan HY. C-reactive protein and ageing. Clin Exp Pharmacol Physiol 2017; 44(Suppl. 1): 9-14.
[http://dx.doi.org/10.1111/1440-1681.12758] [PMID: 28378496]
[16]
ATS committee on Proficiency standards for clinical pulmonary function laboratories. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166(1): 111-7.
[http://dx.doi.org/10.1164/ajrccm.166.1.at1102] [PMID: 12091180]
[17]
Hamer M, Molloy GJ. Association of C-reactive protein and muscle strength in the English longitudinal study of ageing. Age (Dordr) 2009; 31(3): 171-7.
[http://dx.doi.org/10.1007/s11357-009-9097-0] [PMID: 19466582]
[18]
Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart As-sociation. Circulation 2003; 107(3): 499-511.
[http://dx.doi.org/10.1161/01.CIR.0000052939.59093.45] [PMID: 12551878]
[19]
Wåhlin-Larsson B, Wilkinson DJ, Strandberg E, Hosford-Donovan A, Atherton PJ, Kadi F. Mechanistic links underlying the impact of C-reactive protein on muscle mass in elderly. Cell Physiol Biochem 2017; 44(1): 267-78.
[http://dx.doi.org/10.1159/000484679] [PMID: 29130969]
[20]
Taaffe DR, Harris TB, Ferrucci L, Rowe J, Seeman TE. Cross-sectional and prospective relationships of interleukin-6 and C-reactive pro-tein with physical performance in elderly persons: MacArthur studies of successful aging. J Gerontol A Biol Sci Med Sci 2000; 55(12): M709-15.
[http://dx.doi.org/10.1093/gerona/55.12.M709] [PMID: 11129392]
[21]
Shokri-Mashhadi N, Moradi S, Heidari Z, Saadat S. Association of circulating C-reactive protein and high-sensitivity C-reactive protein with components of sarcopenia: A systematic review and meta-analysis of observational studies. Exp Gerontol 2021; 150(15): 111330.
[http://dx.doi.org/10.1016/j.exger.2021.111330] [PMID: 33848566]
[22]
Basualto-Alarcon C, Varela D, Duran J, Duran R, Maass R, Estrada M. Sarcopenia and androgens: A link between pathology and treat-ment. Front Endocrinol 2014.
[http://dx.doi.org/10.3389/fendo.2014.00217]
[23]
Sakuma K, Yamaguchi A. Sarcopenia and age-related endocrine function. Int J Endocrinol 2012; 2012: 127362.
[http://dx.doi.org/10.1155/2012/127362] [PMID: 22690213]
[24]
Priego T, Martín AI, González-Hedström D, Granado M, López-Calderón A. Role of hormones in sarcopenia. Vitam Horm 2021; 115: 535-70.
[http://dx.doi.org/10.1016/bs.vh.2020.12.021] [PMID: 33706961]
[25]
Gillon A, Nielsen K, Steel C, Cornwall J, Sheard P. Exercise attenuates age-associated changes in motoneuron number, nucleocytoplasmic transport proteins and neuromuscular health. Geroscience 2018; 40(2): 177-92.
[http://dx.doi.org/10.1007/s11357-018-0020-4] [PMID: 29736782]
[26]
Gillon A, Steel C, Cornwall J, Sheard P. Increased nuclear permeability is a driver for age-related motoneuron loss. Geroscience 2020; 42(3): 833-47.
[http://dx.doi.org/10.1007/s11357-020-00155-7] [PMID: 32002784]
[27]
Elosua R, Bartali B, Ordovas JM, Corsi AM, Lauretani F, Ferrucci L. Association between physical activity, physical performance, and inflammatory biomarkers in an elderly population: The InCHIANTI study. J Gerontol A Biol Sci Med Sci 2005; 60(6): 760-7.
[http://dx.doi.org/10.1093/gerona/60.6.760] [PMID: 15983180]
[28]
Wyczalkowska-Tomasik A, Czarkowska-Paczek B, Zielenkiewicz M, Paczek L. Inflammatory markers change with age, but do not fall beyond reported normal ranges. Arch Immunol Thher Expo (Warsz) 64: 249-54.
[http://dx.doi.org/10.1007/s00005-015-0357-7]
[29]
Soysal P, Stubbs B, Lucato P, et al. Inflammation and frailty in the elderly: A systematic review and meta-analysis. Ageing Res Rev 2016; 31: 1-8.
[http://dx.doi.org/10.1016/j.arr.2016.08.006] [PMID: 27592340]
[30]
Bano G, Trevisan C, Carraro S, et al. Inflammation and sarcopenia: A systematic review and meta-analysis. Maturitas 2017; 96: 10-5.
[http://dx.doi.org/10.1016/j.maturitas.2016.11.006] [PMID: 28041587]
[31]
de Mattos Margutti KM, Schuch NJ, Schwanke CHA. Inflammatory markers, sarcopenia and its diagnostic criteria among the elderly: A systematic review. Rev Bras Geriatr Gerontol 2017; 20(3): 441-53.
[http://dx.doi.org/10.1590/1981-22562017020.160155]
[32]
Larsson L, Degens H, Li M, et al. Sarcopenia: Aging-related loss of muscle mass and function. Physiol Rev 2019; 99(1): 427-511.
[http://dx.doi.org/10.1152/physrev.00061.2017] [PMID: 30427277]
[33]
Broekhuizen R, Wouters EFM, Creutzberg EC, Schols AMWJ. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61(1): 17-22.
[http://dx.doi.org/10.1136/thx.2005.041996] [PMID: 16055618]
[34]
Radenovic S, Loncar G, Busjahn A, et al. Systemic inflammation and functional capacity in elderly heart failure patients. Clin Res Cardiol 2018; 107(4): 362-7.
[http://dx.doi.org/10.1007/s00392-017-1195-x] [PMID: 29396658]
[35]
Rahimi K, Secknus MA, Adam M, et al. Correlation of exercise capacity with high-sensitive C-reactive protein in patients with stable cor-onary artery disease. Am Heart J 2005; 150(6): 1282-9.
[http://dx.doi.org/10.1016/j.ahj.2005.01.006] [PMID: 16338272]
[36]
Szortyka MFV, Cristiano VB, Ceresér KM, et al. Physical functional capacity and C-reactive protein in schizophrenia. Front Psychiatry 2016; 7: 131.
[http://dx.doi.org/10.3389/fpsyt.2016.00131] [PMID: 27547191]
[37]
Church TS, Barlow CE, Earnest CP, Kampert JB, Priest ELP, Blair SN. Associations between cardiorespiratory fitness and C-reactive pro-tein in men. Arterioscler Thromb Vasc Biol 2002; 22(11): 1869-76.
[http://dx.doi.org/10.1161/01.ATV.0000036611.77940.F8] [PMID: 12426218]
[38]
Colbert LH, Visser M, Simonsick EM, et al. Physical activity, exercise, and inflammatory markers in older adults: Findings from the Health, Aging and Body Composition Study. J Am Geriatr Soc 2004; 52(7): 1098-104.
[http://dx.doi.org/10.1111/j.1532-5415.2004.52307.x] [PMID: 15209647]
[39]
Hemati F, Rahmani A, Asadollahi K, Soleimannejad K, Khalighi Z. Effects of complementary creatine monohydrate and physical training on inflammatory and endothelial dysfunction markers among heart failure patients. Asian J Sports Med 2016; 7(1): e28578.
[http://dx.doi.org/10.5812/asjsm.28578] [PMID: 27217930]
[40]
Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: A systematic review. J Am Coll Cardiol 2005; 45(10): 1563-9.
[http://dx.doi.org/10.1016/j.jacc.2004.12.077] [PMID: 15893167]
[41]
Martín-Ponce E, Hernández-Betancor I, González-Reimers E, Hernández-Luis R, Martínez-Riera A, Santolaria F. Prognostic value of phys-ical function tests: Hand grip strength and six-minute walking test in elderly hospitalized patients. Sci Rep 2014; 4(1): 7530.
[http://dx.doi.org/10.1038/srep07530] [PMID: 25531922]
[42]
Tiksnadi BB, Aziz M, Chesario MS, et al. Functional capacity improvement related to inflammatory marker reduction after phase II cardi-ac rehabilitation program in postrevascularization coronary artery disease patients. ACI 2019; 5(1): 19-34.
[http://dx.doi.org/10.22146/aci.44548] [PMID: 30625501]